Clinical Research Directory
Browse clinical research sites, groups, and studies.
Selective Avoidance of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy In HER-2 Positive/Triple Negative Breast Cancer Patients With Excellent Radiologic Response to the Breast and Axilla, Prospective, Multi-center, Single-arm (ASLAN) Study
Sponsor: Jeong Eon Lee
Summary
The aims of this study is to evaluate 5 year recurrence free survival when omit sentinel lymph node biopsy after neoadjuvant chemotherapy in triple negative or HER-2 positive breast cancer patients when physical examination expected complete remission. And radiological expected Tumor size ≤ 2cm or non-mass enhancement ≤ 4cm.
Official title: Selective Avoidanve of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy In HER-2 Positive/Triple Negative Breast Cancer Patients With Excellent Radiologic Response to the Breast and Axilla, Prospective, Multi-center, Single-arm Study
Key Details
Gender
FEMALE
Age Range
20 Years - 69 Years
Study Type
INTERVENTIONAL
Enrollment
178
Start Date
2021-09-27
Completion Date
2028-12-31
Last Updated
2024-01-26
Healthy Volunteers
No
Conditions
Interventions
avoid axillary sentinel lymph node biopsy after neoadjuvant chemotherapy
Selective Omission of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy In HER-2 positive/Triple Negative Breast Cancer Patients with Excellent Radiologic Response to the Breast and Axilla
Locations (1)
Samsung Medical Center
Seoul, South Korea